Year: 2020
Type: article
Abstract: There was a new report for once-weekly Novo Nordisk's insulin icodec. After subcutaneous injection, the blood concentration reaches its maximum in 16 hours, and the half-life is about 1 week. The phase II clinical trial showed i) subjects were 247 type 2 diabetes, 59.6 ± 8.9 years, BMI 31.3 ± 4.6, HbA1c 8.0 ± 0.7%, FPG 181 ± 42 mg/dL, ii) For 26 weeks, HbA1c improved from 8.1% to 6.7% in group Ico and from 8.0% to 6.9% in group Gla with no significant difference, iii) significantly markers superior to Group Ico included changes in the mean daily glucose profile and time period of 70-140 mg/dL by CGM. Insulin icodec will hopefully develop smooth next phase trial.
Author: Hiroshi Bando
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3126760817